These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. Timmer-Bonte JN, Adang EM, Smit HJ, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC. J Clin Oncol; 2006 Jul 01; 24(19):2991-7. PubMed ID: 16682725 [Abstract] [Full Text] [Related]
38. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients. Garg P, Rana F, Gupta R, Buzaianu EM, Guthrie TH. Breast J; 2009 Jul 01; 15(4):404-8. PubMed ID: 19508671 [Abstract] [Full Text] [Related]
39. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. DeMichele A, Putt M, Zhang Y, Glick JH, Norman S. Cancer; 2003 May 01; 97(9):2150-9. PubMed ID: 12712466 [Abstract] [Full Text] [Related]
40. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH. Pharmacoeconomics; 2012 Feb 01; 30(2):103-18. PubMed ID: 21967155 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]